Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope (R) registry
Jeffrey D Jenks, Danila Seidel, Oliver A Cornely, Sharon Chen, Sebastiaan van Hal, Carol Kauffman, Marisa H Miceli, Melina Heinemann, Martin Christner, Alfredo Jover Saenz, Alexander Burchardt, Bjoern Kemmerling, Raoul Herbrecht, Joerg Steinmann, Shmuel Shoham, Sandra Graeber, Livio Pagano, Dries Deeren, Monica A Slavin, Martin Hoenigl
Mycoses | WILEY | Published : 2020
OBJECTIVES: Invasive fungal infections caused by Lomentospora prolificans are associated with very high mortality rates and can be challenging to treat given pan-drug resistance to available antifungal agents. The objective of this study was to describe the clinical presentation and outcomes in a cohort of patients with invasive L prolificans infections. METHODS: We performed a retrospective review of medical records of patients with invasive L prolificans infection in the FungiScope® registry of rare invasive fungal infections. Patients diagnosed between 01 January 2008 and 09 September 2019 were included in for analysis. RESULTS: The analysis included 41 patients with invasive L prolifican..View full abstract
FungiScope (R) is supported by unrestricted grants of Amplyx Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutics, F2G Ltd., Matinas BioPharma, and Pfizer Inc. FungiScope (R) has been supported by unrestricted grants of Astellas Pharma GmbH, Gilead Sciences GmbH, MSD Sharp & Dohme GmbH, and SCYNEXIS Inc. The MSG 06 study was supported by Astellas, Gilead, and Merck.